The metabolic switch to glycolysis was demonstrated in CD44+CD24lowEPCAM+ CSCs in breast cancer, radioresistant CSCs in nasopharyngeal carcinoma, and CD133+CD49f+ CSCs in hepatocellular carcinoma. This evidence concerns the gene PROM1 and breast carcinoma.